Comparative Pharmacology
Head-to-head clinical analysis: MYCOPHENOLATE MOFETIL HYDROCHLORIDE versus NEORAL.
Peer-Reviewed Evidence
Head-to-head clinical analysis: MYCOPHENOLATE MOFETIL HYDROCHLORIDE versus NEORAL.
MYCOPHENOLATE MOFETIL HYDROCHLORIDE vs NEORAL
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Mycophenolate mofetil hydrochloride is a prodrug of mycophenolic acid (MPA), a selective, reversible inhibitor of inosine monophosphate dehydrogenase (IMPDH). This enzyme is crucial for de novo guanosine nucleotide synthesis in T and B lymphocytes, leading to inhibition of lymphocyte proliferation and antibody production.
Cyclosporine, the active ingredient in Neoral, is a calcineurin inhibitor. It binds to cyclophilin, forming a complex that inhibits calcineurin, thereby preventing dephosphorylation and nuclear translocation of NF-AT (nuclear factor of activated T-cells). This inhibits transcription of interleukin-2 and other cytokines, reducing T-cell activation and proliferation.
Oral: 1-1.5 g twice daily; intravenous: 1 g over 2 hours twice daily.
Initial dose 10-15 mg/kg/day orally divided q12h, then taper by 5% weekly to maintenance of 3-5 mg/kg/day divided q12h. For psoriasis: 2.5 mg/kg/day orally divided q12h. For rheumatoid arthritis: 2.5-5 mg/kg/day orally divided q12h. Administer consistently with or without food.
None Documented
None Documented
The terminal elimination half-life of MPA is approximately 17.9 hours (range 11.7–30.9 hours) in healthy volunteers. In renal transplant patients, half-life may be prolonged to 16.6 ± 6.2 hours. This supports twice-daily dosing with monitoring of trough levels for efficacy and toxicity.
Terminal elimination half-life: 8.4 hours (range 6–24 hours) in healthy volunteers; prolonged in hepatic impairment (up to 20 hours).
Mycophenolic acid (MPA), the active metabolite, is primarily excreted in urine as the glucuronide conjugate (MPAG). Approximately 87% of an administered dose is recovered in urine, with <1% as unchanged MPA. Fecal excretion accounts for about 6% of the dose, mainly as MPAG via biliary secretion.
Primarily biliary/fecal (94%): 94% of dose eliminated in feces via bile, 6% in urine (0.1% unchanged). Minimal renal elimination of parent drug.
Category D/X
Category C
Immunosuppressant
Immunosuppressant